Zydus receives USFDA approval for Enzalutamide capsules

Zydus receives USFDA approval for Enzalutamide capsules


Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg (USRLD: Xtandi Capsules, 40 mg).

Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer. Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad.

Enzalutamide capsules, 40 mg had annual sales of USD 869.4 mn in the United States (IQVIA MAT July 2024).

Click here to connect with us on WhatsApp

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 28 2024 | 2:21 PM IST



Source link

Zydus receives USFDA approval for Enzalutamide capsules

Bandhan Bank announces resignation of Chief Technology Officer


With effect from 24 December 2024

Bandhan Bank announced that Manoj Kumar Mauni, Chief
Technology Officer of the Bank, has tendered his resignation from the services of the Bank. He would continue with the services
in terms of the policies of the Bank, and his last working day with the Bank would be 24 December 2024.

Powered by Capital Market – Live News

Click here to connect with us on WhatsApp

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 28 2024 | 2:13 PM IST



Source link

Zydus receives USFDA approval for Enzalutamide capsules

Alembic Pharma's Panelav unit gets EIR from USFDA


Alembic Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had issued an establishment inspection report (EIR) for its oral solid formulation facility (F-1) located in Panelav, Gujarat.

Earlier, on 26 July 2024, the pharmaceutical company informed that it had successfully completed the USFDA inspection of its Oral Solid Formulation Facility (F-I) in Panelav.

This scheduled GMP inspection was completed without any form 483 observations. The inspection had been conducted from 17 July 2024 to 26 July 2024.

Click here to connect with us on WhatsApp

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.

 

The pharmaceutical companys consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.

Shares of Alembic Pharma shed 0.27% to settle at Rs 1,192.65 on Friday 27 September 2024.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 28 2024 | 1:02 PM IST



Source link

Zydus receives USFDA approval for Enzalutamide capsules

Alembic Pharma's Panelav unit gets EIR from USFDA


Alembic Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had issued an establishment inspection report (EIR) for its oral solid formulation facility (F-1) located in Panelav, Gujarat.

Earlier, on 26 July 2024, the pharmaceutical company informed that it had successfully completed the USFDA inspection of its Oral Solid Formulation Facility (F-I) in Panelav.

This scheduled GMP inspection was completed without any form 483 observations. The inspection had been conducted from 17 July 2024 to 26 July 2024.

Click here to connect with us on WhatsApp

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.

 

The pharmaceutical companys consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.

Shares of Alembic Pharma shed 0.27% to settle at Rs 1,192.65 on Friday 27 September 2024.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 28 2024 | 1:02 PM IST



Source link

Zydus receives USFDA approval for Enzalutamide capsules

Bajel Projects wins first data centre order


Bajel Projects announced that it had successfully entered the emerging data centre segment by securing its first order from an upcoming data centre service provider.

The order involves the design and construction of a 220/33kV gas-insulated switchgear (GIS) substation and transmission line extension for a colocation data centre in Navi Mumbai, Maharashtra.

This project, underscores Bajels strategic entry into the rapidly growing data center market driven by Indias digital transformation, increasing demand for data storage and processing capabilities, it added.

Click here to connect with us on WhatsApp

Bajel will leverage its extensive expertise in design, engineering, procurement, and construction (EPC) to deliver critical power infrastructure solutions. The project will incorporate a combination of lattice towers and monopoles, conductors, and other essential components like the GIS substation, ensuring reliable, efficient, and continuous power supply.

 

Bajel is committed to completing this project within the stipulated timeframe, executing it with strict adherence to quality and safety standards. This commitment will further solidify Bajels reputation for safety and operational excellence, as stated in a press release.

Rajesh Ganesh, MD & CEO of Bajel Projects said, “The exponential growth of data centers in India, fuelled by cloud adoption, e-commerce, digital services and localization, presents a compelling opportunity for us. We’re strategically building capabilities in GIS and Monopoles to become a trusted partner for data center developers in their pursuit of reliable and sustainable power infrastructure.”

Bajel Projects (BPL) is a leading company in the business of power infrastructure, with a strong presence in the Power Transmission and Power Distribution sectors. BPL was formerly part of Bajaj Electricals under the EPC segment.

The company reported standalone net profit of Rs 5.52 crore in Q1 FY25 as against net loss of Rs 1.70 crore posted in Q1 FY24. Net sales stood at Rs 505.69 crore in Q1 FY25, steeply higher than Rs 197.26 crore reported in Q1 FY24.

Shares of Bajel Projects fell 0.14% to end at Rs 254.40 on Friday, 27 September 2024.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 28 2024 | 12:11 PM IST



Source link

Zydus receives USFDA approval for Enzalutamide capsules

Saksoft acquires Bangalore-based Salesforce Summit Partner 'Ceptes Software'


Saksoft announced the acquisition of Ceptes Software, a recognized expert in Salesforce services, headquartered in Bengaluru, Karnataka.

Saksoft stated that it anticipates the transaction will be closed within 4 weeks pending customary closing conditions. This strategic acquisition will significantly help Saksoft expand its capabilities around Salesforce solutions, cloud innovation, and customer experience optimization.

Click here to connect with us on WhatsApp

Ceptes with its 15+ years of experience and as a Salesforce Summit Partner, leverages Salesforce’s full ecosystem, from Sales Cloud and Service Cloud to advanced platforms like Einstein AI and Data Cloud, helping businesses optimize their processes and enhance customer engagement.

 

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 28 2024 | 11:30 AM IST



Source link

YouTube
Instagram
WhatsApp